A business in context

ANTX research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-20 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-10-12 · 0001193125-26-420643

  2. 4 · Ownership change

    Report date 2026-10-12 · 0001193125-26-420641

  3. 4 · Ownership change

    Report date 2026-10-12 · 0001193125-26-420639

  4. 4 · Ownership change

    Report date 2026-09-15 · 0001193125-26-393274

  5. 4 · Ownership change

    Report date 2026-09-09 · 0001193125-26-389545

  6. 4 · Ownership change

    Report date 2026-09-03 · 0001193125-26-385511

  7. 4 · Ownership change

    Report date 2026-09-01 · 0001193125-26-383697

  8. 4 · Ownership change

    Report date 2026-09-01 · 0001193125-26-380595

  9. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-344569

  10. 8-K · Current report

    Report date 2026-08-11 · 0001193125-26-344549 · Items 2.02,9.01

  11. 8-K · Current report

    Report date 2026-06-03 · 0001193125-26-262264 · Items 5.07

  12. 8-K · Current report

    Report date 2026-06-04 · 0001193125-26-257430 · Items 7.01,8.01,9.01

  13. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-216755

  14. 8-K · Current report

    Report date 2026-05-11 · 0001193125-26-216752 · Items 2.02,9.01

  15. DEF 14A · Proxy statement

    Report date 2026-04-22 · 0001193125-26-170314

  16. 8-K · Current report

    Report date 2026-04-09 · 0001193125-26-149822 · Items 8.01,9.01

  17. 8-K · Current report

    Report date 2026-03-19 · 0001193125-26-117765 · Items 5.02

  18. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-110693

  19. 8-K · Current report

    Report date 2026-03-17 · 0001193125-26-110681 · Items 2.02,9.01

  20. 8-K · Current report

    Report date 2026-03-08 · 0001193125-26-099169 · Items 1.01,3.02,7.01,9.01

  21. 8-K · Current report

    Report date 2026-01-26 · 0001193125-26-029540 · Items 5.02

  22. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-277673

  23. 8-K · Current report

    Report date 2025-11-12 · 0001193125-25-277662 · Items 2.02,9.01

  24. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-107301

  25. 8-K · Current report

    Report date 2025-08-12 · 0000950170-25-107278 · Items 9.01

  26. 8-K · Current report

    Report date 2025-06-17 · 0001193125-25-143187 · Items 3.02,9.01

  27. 8-K · Current report

    Report date 2025-06-11 · 0001193125-25-138796 · Items 7.01,9.01

  28. 8-K · Current report

    Report date 2025-05-22 · 0001193125-25-127595 · Items 5.07

  29. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-070358

  30. 8-K · Current report

    Report date 2025-05-13 · 0000950170-25-070305 · Items 9.01

  31. 8-K · Current report

    Report date 2025-05-01 · 0001193125-25-110019 · Items 7.01,9.01

  32. DEF 14A · Proxy statement

    Report date 2025-04-10 · 0000950170-25-052852

  33. 10-K · Annual report

    Report date 2024-12-31 · 0000950170-25-044366

  34. 8-K · Current report

    Report date 2025-03-25 · 0000950170-25-044353 · Items 2.02,9.01

  35. SC 13G/A · Ownership disclosure

    0001104659-24-118948

  36. SC 13G/A · Ownership disclosure

    0000921895-24-002722

  37. SC 13G/A · Ownership disclosure

    0001193125-24-257248

  38. 10-Q · Quarterly report

    Report date 2024-09-30 · 0000950170-24-126282

  39. 8-K · Current report

    Report date 2024-11-13 · 0000950170-24-126276 · Items 2.02,9.01

  40. 8-K · Current report

    Report date 2024-11-04 · 0001193125-24-251240 · Items 5.02

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 1 transaction rows1PSale: 10 transaction rows10SGrant / award: 5 transaction rows5AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 1 transaction rows1G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

17 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-09-15
2026-09-16
Trenor Cameron C. IIIA · Grant / award
Acquired
Common Stock116667.00.0
2026-09-15
2026-09-16
Trenor Cameron C. IIIA · Grant / award
Acquired
Stock Option (right to by)
Derivative security
233333.00.0
2026-09-09
2026-09-11
Readnour Robin ShaneS · Sale
Disposed
Common Stock585.06.02
2026-09-09
2026-09-11
Readnour Robin ShaneS · Sale
Disposed
Common Stock523.06.02
2026-09-08
2026-09-08
Readnour Robin ShaneS · Sale
Disposed
Common Stock4725.06.02
2026-09-08
2026-09-08
Readnour Robin ShaneS · Sale
Disposed
Common Stock5294.06.02
2026-09-03
2026-09-08
Readnour Robin ShaneS · Sale
Disposed
Common Stock2877.06.07
2026-09-03
2026-09-08
Readnour Robin ShaneS · Sale
Disposed
Common Stock3223.06.07
2026-09-01
2026-09-04
Williams Sarah JoanneS · Sale
Disposed
Common Stock272.05.53
2026-09-01
2026-09-02
FitzPatrick Margaret MP · Purchase
Acquired
Common Stock2098.05.53
2026-08-17
2026-08-19
Readnour Robin ShaneS · Sale
Disposed
Common Stock16696.06.01
2026-08-17
2026-08-19
Readnour Robin ShaneS · Sale
Disposed
Common Stock18706.06.01
2026-08-14
2026-08-14
Zakrzewski Joseph SG · Gift
Disposed
Common Stock405880.00.0
2026-07-10
2026-07-10
Aziz KabeerA · Grant / award
Acquired
Common Stock2852.00.0
2026-07-10
2026-07-10
Marks Gilbert LynnA · Grant / award
Acquired
Common Stock2789.00.0
2026-07-10
2026-07-10
Martin Patricia A.A · Grant / award
Acquired
Common Stock766.00.0
2026-07-08
2026-07-10
Eizen Joshua MS · Sale
Disposed
Common Stock5945.04.17

Identity & relationships

Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001880438AN2 Therapeutics, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records

Search names and former names

    Revenue in constant purchasing power

    USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

    No USD annual revenue periods with complete CPI coverage are available. Non-USD statements are not converted with U.S. CPI.

    Bureau of Labor Statistics · retrieved 2026-10-20 · 9 selected series; gaps remain missing

    Explore the CPI history ↗